机构：[1]Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University,Guangzhou, China广东省人民医院[2]Department of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden[3]Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Eye Institute,Southern Medical University, Guangzhou, China广东省人民医院[4]Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, China[5]MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Key Laboratory of Pathogen Bioscience and Anti‐infective Medicine,Department of Bioinformatics, Center for Systems Biology, School of Biology and Basic Medical Sciences, Suzhou Medical College of SoochowUniversity, Suzhou, China[6]Department of Ultrasound, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[7]Department of Orthopaedics, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[8]Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease‐related Molecular Network,West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[9]School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, China[10]School of Medicine, Institute of Medical Sciences, Örebro University, Örebro, Sweden[11]Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China苏州大学附属第二医院[12]Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden[13]Key Laboratory of Public Health Safety, School of Public Health, Fudan University, Shanghai, China[14]Department of Otolaryngology, Guangzhou Women and Children's Medical Centre, Guangzhou, China[15]School of Medicine, The Chinese University of Hong Kong, Shenzhen, Shenzhen, China[16]Department of Mathematics, University of California, San Diego, California, USA[17]Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China广东省人民医院[18]Institutes for Systems Genetics, Frontiers Science Center for Disease‐Related Molecular Network, West China Hospital, Sichuan University,Chengdu, China四川大学华西医院
The rapidly evolving landscape of biomarkers for colorectal cancer (CRC) necessitates an integrative, updated repository. In response, we constructed the Colorectal Cancer Biomarker Database (CBD), which collected and displayed the curated biomedicine information for 870 CRC biomarkers in the previous study. Building on CBD, we have now developed CBD2, which includes information on 1569 newly reported biomarkers derived from different biological sources (DNA, RNA, protein, and others) and clinical applications (diagnosis, treatment, and prognosis). CBD2 also incorporates information on nonbiomarkers that have been identified as unsuitable for use as biomarkers in CRC. A key new feature of CBD2 is its network analysis function, by which users can investigate the visible and topological network between biomarkers and identify their relevant pathways. CBD2 also allows users to query a series of chemicals, drug combinations, or multiple targets, to enable multidrug, multitarget, multipathway analyses, toward facilitating the design of polypharmacological treatments for CRC. CBD2 is freely available at . CBD2 integrates biomarkers derived from diverse biological sources and clinical applications, employing a standardized approach for annotation and classification. CBD2 facilitates precision medicine in colorectal cancer by providing abundant data, including drug-target information and visualized network analysis functions. With its user-friendly interface, CBD2 aids in the identification and development of biomarkers for colorectal cancer.Highlightsimage CBD2 integrates biomarkers derived from diverse biological sources and clinical applications, employing a standardized approach for annotation and classification.CBD2 facilitates precision medicine in colorectal cancer by providing abundant data, including drug-target information and visualized network analysis functions.With its user-friendly interface, CBD2 aids in the identification and development of biomarkers for colorectal cancer.
基金：
National Natural Science Foundation of China; GDPH Supporting Fund for Talent Program [KJ012020633, KJ012019530]; Guangdong Provincial People's Hospital; Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application [2022B1212010011]; [32200545]; [32271292]
第一作者机构：[1]Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University,Guangzhou, China[2]Department of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden[3]Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangdong Eye Institute,Southern Medical University, Guangzhou, China[4]Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, China
共同第一作者：
通讯作者：
通讯机构：[2]Department of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden[5]MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Key Laboratory of Pathogen Bioscience and Anti‐infective Medicine,Department of Bioinformatics, Center for Systems Biology, School of Biology and Basic Medical Sciences, Suzhou Medical College of SoochowUniversity, Suzhou, China[10]School of Medicine, Institute of Medical Sciences, Örebro University, Örebro, Sweden[*1]MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Key Laboratory of Pathogen Bioscience and Anti‐infective Medicine,Department of Bioinformatics, School of Biology and Basic Medical Sciences, Center for Systems Biology, Suzhou Medical College of Soochow University, Suzhou, China.[*2]School of Medicine, Institute of Medical Sciences, Örebro University, Örebro, Sweden.[*3]Department of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
推荐引用方式(GB/T 7714)：
Xueli Zhang,Min Li,Siting Ye,et al.CBD2: A functional biomarker database for colorectal cancer[J].Imeta.2023,doi:10.1002/imt2.155.
APA：
Xueli Zhang,Min Li,Siting Ye,Ke Shen,Haining Yuan...&Xiao‐Feng Sun.(2023).CBD2: A functional biomarker database for colorectal cancer.Imeta,,
MLA：
Xueli Zhang,et al."CBD2: A functional biomarker database for colorectal cancer".Imeta .(2023)
